Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome

Fig. 2

CCR5 Activation by RANTES in Model MDA-MB-231 Cell Line. a MB231 cells show overlapping cytoplasm (green) and nucleus (light blue), with or without CCR5 signal (red). MB231 cells without the addition of RANTES are devoid of CCR5 (top panels). MB231 with the addition of RANTES shows CCR5 positivity (bottom panels), including CCR5 pools (white arrow). b In cells not exposed to RANTES, a majority of cells (~ 71%) are CCR5 (−) and 29% of cells being low CCR5 expressing ( +). In contrast, after exposure to RANTES, 9% of cells remained CCR5 (−), with the majority (~ 91%) being medium or high expressing for CCR5. c Cells not exposed to RANTES had low CCR5 expression on the surface and within the nucleus. In contrast, the addition of RANTES had high expression/upregulation of CCR5 signal on the cell and within the nucleus

Back to article page